Compass Associates
Multi-award-winning recruitment consultancy dedicated to the independent Health, Social Care and Children's Services sectors.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
GlaxoSmithKline subsidiary ViiV Healthcare has reported new data for its two-drug HIV regimen Dovato, with hopes that the long-term data could encourage clinicians to switch from other triple regimen therapies.